29th May 2024

Professor Andrew Seaton has taken up his post as president of the British Society for Antimicrobial Chemotherapy (BSAC), having been voted in as president-elect one year ago at the society’s 2023 annual general meeting. He takes over from former President Dr David Jenkins who has successfully completed his three-year tenure and will now become BSAC Vice President.

Andrew has been a Consultant in Infectious Diseases & General Medicine in NHS Greater Glasgow and Clyde since 2000 and he is an Honorary Professor in Glasgow University. Andrew established and leads the NHS Greater Glasgow and Clyde OPAT service and Antimicrobial Management Team and is a founding member of the Scottish Antimicrobial Prescribing Group which he has chaired since 2017. Andrew has worked with the Scottish Government’s urgent and unscheduled care group to support the development of OPAT and other admission avoidance/ supported discharge services and with Mark Gilchrist he co-authored the BSAC OPAT MOOC and co-leads the BSAC OPAT initiative.

“It is a huge honour to have been elected as President of the Society which I have been a member of for more than 25 years. The breadth and depth of BSAC’s involvement and influence across the field of antimicrobial chemotherapy and infection prevention and management in its broadest sense, not just in the UK but globally, is truly remarkable. I would like to congratulate David Jenkins on his tenure as president. David successfully steered the Society through the pandemic and conceived and led the development of GAMSAS. He is a very hard act to follow.”

“As we attempt to reset within a highly disrupted healthcare system in the UK, there are major challenges with respect to stewardship of antimicrobials and containing drug-resistant infections ahead. The Society fully endorses the recently published UK 5-year national action plan to support containing AMR. BSAC will be engaged closely in solutions as part of the implementation process including but not limited to use of GAMSAS as a lever for local AMS service development and quality improvement. GAMSAS will also support the UK commitment to AMR containment in low-and-middle-income countries (LMICs) where healthcare systems are challenged and resources limited.”

“Strengthening AMS and AMR control through a truly multidisciplinary approach, acknowledging the significant role and potential of nurses and pharmacists in clinical decision making and provision and prescription of antimicrobials, including in LMICs, is a really important area for the Society with respect to both design of educational resources and professional and political advocacy.”

“It is important to acknowledge that ensuring availability of life-saving WHO Access antibiotics and appropriate water, sanitation and hygiene is of primary importance for much of the world both to prevent and treat infection as well as mitigate again AMR. New antimicrobials also are essential for the current and future treatment of established and emerging drug-resistant infections. The Society firmly supports the UK’s vision to promote the development of new antimicrobials through the novel delinkage scheme. BSAC’s UKAR project is also currently collecting indication and outcome data on newly licensed agents which will help inform this initiative and help us understand the real-world use of these new agents. The Society will continue to advocate for global uptake of the delinkage model which will be crucial to ensure that success (as judged by ongoing research, development and Pharma investment in new antimicrobial development) is sustained.”

Professor Seaton will serve as the BSAC president until 2027.

 

GP? Pharmacist? Researcher? Social Scientist? Whatever field you work in, if you’re committed to fighting infection then we want you to join us as a BSAC Member.
Become a member

Having trouble finding what you're after?

Top